Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells.

Guzzetti, Carlotta; Corno, Cristina; Vergani, Elisabetta; Mirra, Luca; Ciusani, Emilio; Rodolfo, Monica; Perego, Paola; Beretta, Giovanni L

Guzzetti, Carlotta; Corno, Cristina; Vergani, Elisabetta; Mirra, Luca; Ciusani, Emilio; Rodolfo, Monica; Perego, Paola; Beretta, Giovanni L.

Afiliação

Guzzetti C; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Corno C; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Vergani E; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Mirra L; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Ciusani E; Laboratory of Clinical Pathology and Medical Genetics, Istituto Neurologico Fondazione C. Besta, Milan, Italy.
Rodolfo M; Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Perego P; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.
Beretta GL; Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Milan, Italy.

Front Oncol ; 13: 1182853, 2023.

Article em En | MEDLINE | ID: mdl-37790750

Palavras-chave

BRAF; drug resistance; kisspeptins; melanoma; metastasis; vemurafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google